

GLOBAL KINETICS CORPORATION NAMES JOHN SCHELLHORN NEW PRESIDENT AND CEO

Focus Will Include Expanding Digital Health Company's Presence in U.S. Parkinson's Disease Market

Melbourne, Australia, LONDON and MINNEAPOLIS, Oct. 4, 2017 – Global Kinetics Corporation (GKC), a digital health company revolutionizing the management of Parkinson's disease announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company's Board of Directors.

Schellhorn joins GKC with a proven track record to spearhead the company's accelerated growth strategy to meet the demand for its lead product, the Personal KinetiGraph™ (PKG™) system (Parkinson's KinetiGraph™ system outside of the U.S.).

Schellhorn will be US-based as he oversees the company's increasing focus on the world's largest health technology market.

GKC Chairman and Brandon Capital Venture Partner, J. Leighton Read, MD, said: "John is a 33-year veteran of the medical device industry with extensive experience in the commercialization of innovative medical technologies. He has successfully managed and built functions ranging from domestic and international sales force management, clinical, regulatory, global marketing, new market development, manufacturing and joint venture agreements. John has the skills and the passion to lead GKC in the company's next exciting phase of growth."

Prior to joining GKC, Schellhorn was President and CEO of Monteris Medical and Chief Commercialization Officer for Barrx Medical, which was acquired by Covidien. Prior to Barrx, he served as president and CEO of Softscope Medical Technologies, where he executed the sale of the company to Fujifilm in 2008. He has also built a number of businesses for Boston Scientific in Asia and Australia, where he made his home for over a decade. Before embarking on a commercial career, he served 7 years as a US Marine Corps pilot.

"Global Kinetics Corporation is positioned to make a significant positive impact on the lives of millions of people around the world living with Parkinson's disease," said Schellhorn. "Our product, the PKG™, is undoubtedly a market leading and ground breaking health technology addressing an established market need, and the company is on the cusp of significant growth, with great potential to penetrate more markets across the globe."

About GKC and the PKG™ System

GKC, recognized as a Top 10 Most Innovative Health Company by the Fast Company Awards 2017, is a commercial-stage digital health company revolutionizing the management of Parkinson's.

The company's Personal KinetiGraph ('PKG™') System is the only commercially available digital health technology which provides clinically meaningful continuous measurement of the key symptoms of Parkinson's disease. The PKG™ System relies on cloud-based proprietary algorithms that measure bradykinesia, dyskinesia, tremor, sleep and the relationships of these to medication timing.

The PKG™ System records body movements and other symptoms over the course of many days and creates data-driven reports that empower more personalized treatment and management decisions—with the goal of leading to a higher quality of life for patients. The FDA cleared, and European approved, PKG™ System is now used by leading Movement Disorder Specialists in over 200 clinics in 16 countries.

In addition to pursuing pathways for increased use in routine clinical care for Parkinson’s disease, Global Kinetics continues to seek partnerships with major pharmaceutical and medical technology companies who are embracing objective measurement in Parkinson’s to further their own business objectives.

For more information, visit: www.globalkineticscorp.com

- END -

For more information, contact:

Michelle Goldsmith

Global Kinetics Corporation

m: + 61 417 554 632

e: michelle.goldsmith@globalkineticscorp.com

US media relations:

Carolyn Hawley

Canale Communications

o: +1-619-849-5382

e: carolyn@canalecomm.com